Lilly Warns Patients About Counterfeit and Compounded Medicines Releases Open Letter and Takes Further Legal Action Against Counterfeit, Fake, Unsafe, and Untested Products
Lilly Warns Patients About Counterfeit and Compounded Medicines Releases Open Letter and Takes Further Legal Action Against Counterfeit, Fake, Unsafe, and Untested Products
Eli Lilly and Company is committed to meeting the needs of people living with diabetes and obesity with treatment options that change the way healthcare providers can treat these diseases. Today, we are publishing an open letter to ensure that people living with diabetes and obesity, their families, and their healthcare providers are informed about potentially serious risks posed by the proliferation of counterfeit, fake, compounded, and other unsafe or untested versions of our FDA-approved tirzepatide medications (Mounjaro and Zepbound) and about appropriate use of our authentic medicines.
伊利·莉莉公司致力於爲患有糖尿病和肥胖症的人們提供可以改變醫護人員治療這些疾病方式的治療選擇。今天，我們正在發表一封公開信，以確保患有糖尿病和肥胖症的人們、他們的家人以及醫護人員了解到假冒、僞造、混合和其他不安全或未經檢測的版本的FDA批准的替瑞珍肽藥物（Mounjaro）可能帶來的潛在風險，以及我們正版藥物的正確使用。一封公開信爲了確保患有糖尿病和肥胖症的人們、他們的家人以及醫護人員了解到我們FDA批准的替瑞珍肽藥物（Mounjaro）的假冒、僞造、混合和其他不安全或未經檢測的版本帶來的潛在嚴重風險，我們正在發表一封公開信。和Zepbound並且了解我們正版藥物的合適使用。
譯文內容由第三人軟體翻譯。